Relation between leukocyte counts and cortisol secretion in CML patients undergoing combined TNF alpha/IFN alpha therapy
- PMID: 1327178
- DOI: 10.1007/BF01695809
Relation between leukocyte counts and cortisol secretion in CML patients undergoing combined TNF alpha/IFN alpha therapy
Abstract
During long-term interferon alpha-2b (IFN) therapy of Philadelphia chromosome-positive chronic myelogenous leukemia (CML) patients, short-term effects of tumor necrosis factor alpha (TNF) on peripheral leukocyte counts, as well as cortisol and corticotropin (ACTH) release were studied. TNF (40-160 micrograms/m2) was given as a 2-h infusion on 5 consecutive days every 3 weeks, in addition to s.c. daily IFN injections (4 mio U/m2), to four (two male/two female) patients, who had been treated for more than 8 months with IFN and additionally for 0-7 months with TNF. Leukocyte counts, cortisol, and ACTH were determined at 30-min intervals between 4 p.m. and midnight. Profiles were determined the day before and on day 1 of TNF therapy. Leukocyte numbers decreased 30 min after start of TNF administration and increased 30-60 min later with a rebound until the next TNF application. The increase of leukocyte counts was due mostly to neutrophil granulocytes. ACTH levels increased 30 min, cortisol 60 min, and leukocyte counts 90 min after start of TNF infusion. Metopirone, an inhibitor of cortisol synthesis given to one patient, suppressed the TNF-induced stimulation of cortisol secretion and subsequent increase of leukocyte counts, while ACTH blood levels were enhanced. It was concluded that leukocyte count increases after TNF/IFN administration might be related to TNF-evoked cortisol secretion.
Similar articles
-
Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia.J Pediatr Hematol Oncol. 2002 Jan;24(1):18-22. doi: 10.1097/00043426-200201000-00006. J Pediatr Hematol Oncol. 2002. PMID: 11902732 Clinical Trial.
-
Tumor necrosis factor alpha modifies resistance to interferon alpha in vivo: first clinical data.Cancer Immunol Immunother. 1992;35(5):342-6. doi: 10.1007/BF01741148. Cancer Immunol Immunother. 1992. PMID: 1394338 Free PMC article. Clinical Trial.
-
Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.J Clin Oncol. 1992 May;10(5):772-8. doi: 10.1200/JCO.1992.10.5.772. J Clin Oncol. 1992. PMID: 1569449
-
Interferon-alpha therapy for chronic myelogenous leukemia.Am J Med. 1995 Oct;99(4):402-11. doi: 10.1016/s0002-9343(99)80189-2. Am J Med. 1995. PMID: 7573097 Review.
-
Intensive combination chemotherapy in treatment of CML.Bone Marrow Transplant. 1996 May;17 Suppl 3:S55-7. Bone Marrow Transplant. 1996. PMID: 8769703 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical